Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Trial Profile

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG 397 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 21 Oct 2019 Planned End Date changed from 9 Sep 2022 to 27 Apr 2023.
    • 21 Oct 2019 Planned primary completion date changed from 11 Aug 2022 to 29 Mar 2023.
    • 25 Sep 2019 Planned End Date changed from 27 Aug 2023 to 9 Sep 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top